Biography
My ÌÇÐÄ´«Ã½ has focused on rare, monogenetic skin diseases such as Epidermolysis Bullosa (EB) and Gorlin Syndrome (Basal Cell Nevus Syndrome). With my PhD training in basic science, post-doctoral fellowship in clinical ÌÇÐÄ´«Ã½, and residency in dermatology, I am committed to improving the lives of EB patients, to correct their underlying genetic disease and to offer new treatments for their skin and esophageal wounds. I was the PI of the investigator-initiated, Phase 1/2A clinical trial of autologous gene-therapy skin grafts for RDEB (Pz-cel, EB-101, previously called LEAES). I held the IND and have had successful interactions with the FDA Division of Dermatology which led to the successful granting of US orphan drug designation (2016), a Rare Pediatric Disease Designation (2017) and FDA’s Breakthrough Therapy Designation. I have led or co-led the conduct and completion of 10 investigator initiated clinical trials that have been published in high impact journals (NEJM, JAMA, J Clinical Oncology, Lancet Oncology). I have filed multiple INDs and have more than 12 years of clinical/translational experience in rare genetic diseases in dermatology.
View Full Biography
Professional Summary
Education & Certifications
- Internship: Santa Clara Valley Medical Center (2004) CA
- Fellowship: UCSF Dept of Epidemiology and Biostatistics (2008) CA
- Residency: Stanford University Hospital and Clinics - Dermatology Department (2007) CA
-
- Medical Education: Stanford University Hospital and Clinics - Dermatology Department (2003) CA
- Board Certification: American Board of Dermatology, Dermatology (2007)
- Fellow, Univ of Calif, San Francisco, KL2 Clinical Research (2009)
- Resident, Stanford University, Dermatology (2007)
- Intern, Santa Clara Valley, Medicine (2004)
- PhD, Stanford University, Biophysics (2003)
- MD, Stanford University, Medicine (2003)
- BA, UC Berkeley, Biochemistry (1995)
Honors & Awards
- Clinical Investigator Award, Damon Runyon (2011)
- Health Services Investigator Award, American Skin Association (2009)
- K23 Career Development Award, National Institutes of Health (2009 - 2013)
-
- Naomi Kanof Lecture and Prize, Society of Investigative Dermatoloy (2024)
- Research Achievement Award in Skin Cancer, American Skin Association (2023)
- Scholar-Innovator, Harrington Discovery Center (2014-2016)
- Young Investigator Award, Prevent Cancer Organization (2007-2009)
Administrative Appointments
- Co-Director, AACR Molecular Biology in Clinical Oncology Workshop (2015 - Present)
- Director, Clinical Scholars Track, Dept Dermatology (2012 - Present)
- President, American Dermatoepidemiology Network (2013 - 2015)
-
Publications
-
Xeroderma pigmentosum p48 gene enhances global genomic repair and suppresses UV-induced mutagenesis
Tang, J. Y., Hwang, B. J., Ford, J. M., Hanawalt, P. C., & Chu, G. (2000). Xeroderma pigmentosum p48 gene enhances global genomic repair and suppresses UV-induced mutagenesis. MOLECULAR CELL, 5(4), 737–44. -
Interaction between UV-damaged DNA binding activity proteins and the c-Abl tyrosine kinase
Cong, F., Tang, J., Hwang, B. J., Vuong, B. Q., Chu, G., & Goff, S. P. (2002). Interaction between UV-damaged DNA binding activity proteins and the c-Abl tyrosine kinase. JOURNAL OF BIOLOGICAL CHEMISTRY, 277(38), 34870–34878. -
Xeroderma pigmentosum complementation group E and UV-damaged DNA-binding protein
Tang, J., & Chu, G. (2002). Xeroderma pigmentosum complementation group E and UV-damaged DNA-binding protein. DNA REPAIR, 1(8), 601–16. -
-
Toxicity from radiation therapy associated with abnormal transcriptional responses to DNA damage
Rieger, K. E., Hong, W. J., Tusher, V. G., Tang, J., Tibshirani, R., & Chu, G. (2004). Toxicity from radiation therapy associated with abnormal transcriptional responses to DNA damage. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 101(17), 6635–40. -
Xeroderma pigmentosum group C in an isolated region of Guatemala
Cleaver, J. E., Feeney, L., Tang, J. Y., & Tuttle, P. (2007). Xeroderma pigmentosum group C in an isolated region of Guatemala. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 127(2), 493–496. -
Novel Hedgehog pathway targets against basal cell carcinoma
Tang, J. Y., So, P.-L., & Epstein, E. H. (2007). Novel Hedgehog pathway targets against basal cell carcinoma. TOXICOLOGY AND APPLIED PHARMACOLOGY, 224(3), 257–264. -
Statin use and risk of basal cell carcinoma
Asgari, M. A., Tang, J., Epstein, E. H., Chren, M.-M., Warton, E. M., Quesenberry, C. P., … Friedman, G. D. (2009). Statin use and risk of basal cell carcinoma. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 61(1), 66–72. -
Inverse association between serum 25(OH) vitamin D levels and non-melanoma skin cancer in elderly men
Tang, J. Y., Parimi, N., Wu, A., Boscardin, W. J., Shikany, J. M., Chren, M.-M., … Bauer, D. C. (2010). Inverse association between serum 25(OH) vitamin D levels and non-melanoma skin cancer in elderly men. CANCER CAUSES & CONTROL, 21(3), 387–91. -
Association of Prediagnostic Serum Vitamin D Levels with the Development of Basal Cell Carcinoma
Asgari, M. M., Tang, J., Warton, M. E., Chren, M.-M., Quesenberry, C. P., Bikle, D., … Friedman, G. D. (2010). Association of Prediagnostic Serum Vitamin D Levels with the Development of Basal Cell Carcinoma. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 130(5), 1438–1443. -
Basal Cell Carcinoma Chemoprevention with Nonsteroidal Anti-inflammatory Drugs in Genetically Predisposed PTCH1(+/-) Humans and Mice
Tang, J. Y., Aszterbaum, M., Athar, M., Barsanti, F., Cappola, C., Estevez, N., … Epstein, E. H. (2010). Basal Cell Carcinoma Chemoprevention with Nonsteroidal Anti-inflammatory Drugs in Genetically Predisposed PTCH1(+/-) Humans and Mice. CANCER PREVENTION RESEARCH, 3(1), 25–34. -
Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth
Kim, J., Tang, J. Y., Gong, R., Kim, J., Lee, J. J., Clemons, K. V., … Beachy, P. A. (2010). Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth. CANCER CELL, 17(4), 388–99. -
Novel investigational drugs for basal cell carcinoma
So, P.-L., Tang, J. Y., & Epstein, E. H. (2010). Novel investigational drugs for basal cell carcinoma. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 19(9), 1099–1112. -
Association of facial skin aging and vitamin D levels in middle-aged white women
Chang, A. L. S., Fu, T., Amir, O., & Tang, J. Y. (2010). Association of facial skin aging and vitamin D levels in middle-aged white women. CANCER CAUSES & CONTROL, 21(12), 2315–16. -
High Prevalence of Vitamin D Deficiency in Patients With Basal Cell Nevus Syndrome
Tang, J. Y., Wu, A., Linos, E., Parimi, N., Lee, W., Aszterbaum, M., … Epstein, E. H. (2010). High Prevalence of Vitamin D Deficiency in Patients With Basal Cell Nevus Syndrome. ARCHIVES OF DERMATOLOGY, 146(10), 1105–10. -
Genotype-Phenotype Correlations among Pachyonychia Congenita Patients with K16 Mutations
Fu, T., Leachman, S. A., Wilson, N. J., Smith, F. J. D., Schwartz, M. E., & Tang, J. Y. (2011). Genotype-Phenotype Correlations among Pachyonychia Congenita Patients with K16 Mutations. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 131(5), 1025–28. -
Vitamin D3 Inhibits Hedgehog Signaling and Proliferation in Murine Basal Cell Carcinomas
Tang, J. Y., Xiao, T. Z., Oda, Y., Chang, K. S., Shpall, E., Wu, A., … Epstein, E. H. (2011). Vitamin D3 Inhibits Hedgehog Signaling and Proliferation in Murine Basal Cell Carcinomas. CANCER PREVENTION RESEARCH, 4(5), 744–51. -
Correlates of low bone mass in children with generalized forms of epidermolysis bullosa
Bruckner, A. L., Bedocs, L. A., Keiser, E., Tang, J. Y., Doernbrack, C., Arbuckle, H. A., … Bachrach, L. K. (2011). Correlates of low bone mass in children with generalized forms of epidermolysis bullosa. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 65(5), 1001–9. -
Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened
Tang, T., Tang, J. Y., Li, D., Reich, M., Callahan, C. A., Fu, L., … de Sauvage, F. J. (2011). Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened. CLINICAL CANCER RESEARCH, 17(10), 3378–87. -
Hat, shade, long sleeves, or sunscreen? Rethinking US sun protection messages based on their relative effectiveness
Linos, E., Keiser, E., Fu, T., Colditz, G., Chen, S., & Tang, J. Y. (2011). Hat, shade, long sleeves, or sunscreen? Rethinking US sun protection messages based on their relative effectiveness. CANCER CAUSES & CONTROL, 22(7), 1067–71. -
Calcium Plus Vitamin D Supplementation and the Risk of Nonmelanoma and Melanoma Skin Cancer: Post Hoc Analyses of the Women's Health Initiative Randomized Controlled Trial
Tang, J. Y., Fu, T., Leblanc, E., Manson, J. A. E., Feldman, D., Linos, E., … Stefanick, M. L. (2011). Calcium Plus Vitamin D Supplementation and the Risk of Nonmelanoma and Melanoma Skin Cancer: Post Hoc Analyses of the Women's Health Initiative Randomized Controlled Trial. JOURNAL OF CLINICAL ONCOLOGY, 29(22), 3078–84. -
Menopausal Hormone Therapy and Risks of Melanoma and Nonmelanoma Skin Cancers: Women's Health Initiative Randomized Trials
Tang, J. Y., Spaunhurst, K. M., Chlebowski, R. T., Wactawski-Wende, J., Keiser, E., Thomas, F., … Stefanick, M. L. (2011). Menopausal Hormone Therapy and Risks of Melanoma and Nonmelanoma Skin Cancers: Women's Health Initiative Randomized Trials. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 103(19), 1469–75. -
Subcutaneous Nodules in an Elderly Patient Necrobiotic xanthogranuloma
Fu, T., Zwerner, J., Kim, J., & Tang, J. (2011). Subcutaneous Nodules in an Elderly Patient Necrobiotic xanthogranuloma. ARCHIVES OF DERMATOLOGY, 147(10), 1215–20. -
Sun protective behaviors and vitamin D levels in the US population: NHANES 2003-2006
Linos, E., Keiser, E., Kanzler, M., Sainani, K. L., Lee, W., Vittinghoff, E., … Tang, J. Y. (2012). Sun protective behaviors and vitamin D levels in the US population: NHANES 2003-2006. CANCER CAUSES & CONTROL, 23(1), 133–40. -
Pachyonychia congenita patients with mutations in KRT6A have more extensive disease compared with patients who have mutations in KRT16
Spaunhurst, K. M., Hogendorf, A. M., Smith, F. J. D., Lingala, B., Schwartz, M. E., Cywinska-Bernas, A., … Tang, J. Y. (2012). Pachyonychia congenita patients with mutations in KRT6A have more extensive disease compared with patients who have mutations in KRT16. BRITISH JOURNAL OF DERMATOLOGY, 166(4), 875–878. -
Emerging Treatments and Signaling Pathway Inhibitors
Tang, J. Y., & Marghoob, A. A. (2011). Emerging Treatments and Signaling Pathway Inhibitors. SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 30(4), S14–S18. -
Elucidating the Role of Molecular Signaling Pathways in the Tumorigenesis of Basal Cell Carcinoma
Tang, J. Y. (2011). Elucidating the Role of Molecular Signaling Pathways in the Tumorigenesis of Basal Cell Carcinoma. SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 30(4), S6–S9. -
Reliability and prevalence of digital image skin types in the United States: Results from National Health and Nutrition Examination Survey 2003-2004
Keiser, E., Linos, E., Kanzler, M., Lee, W., Sainani, K. L., & Tang, J. Y. (2012). Reliability and prevalence of digital image skin types in the United States: Results from National Health and Nutrition Examination Survey 2003-2004. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 66(1), 163–65. -
Inhibiting the Hedgehog Pathway in Patients with the Basal-Cell Nevus Syndrome
Tang, J. Y., Mackay-Wiggan, J. M., Aszterbaum, M., Yauch, R. L., Lindgren, J., Chang, K., … Epstein, E. H. (2012). Inhibiting the Hedgehog Pathway in Patients with the Basal-Cell Nevus Syndrome. NEW ENGLAND JOURNAL OF MEDICINE, 366(23), 2180–88. -
Nanoelectroablation therapy for murine basal cell carcinoma
Nuccitelli, R., Kevin Tran, K., Athos, B., Kreis, M., Nuccitelli, P., Chang, K. S., … Tang, J. Y. (2012). Nanoelectroablation therapy for murine basal cell carcinoma. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 424(3), 446–50. -
Factors affecting sunscreen use and sun avoidance in a US national sample of organ transplant recipients
Mihalis, E. L., Wysong, A., Boscardin, W. J., Tang, J. Y., Chren, M. M., & Arron, S. T. (2013). Factors affecting sunscreen use and sun avoidance in a US national sample of organ transplant recipients. BRITISH JOURNAL OF DERMATOLOGY, 168(2), 346–353. -
The Evolving Conception and Management Challenges of Malignant Fibrous Histiocytoma
Hollmig, S. T., Kirkland, E. B., Henderson, M. T., Tang, J. Y., & Gladstone, H. B. (2012). The Evolving Conception and Management Challenges of Malignant Fibrous Histiocytoma. DERMATOLOGIC SURGERY, 38(12), 1922–29. -
Sunscreen use in NCAA collegiate athletes: Identifying targets for intervention and barriers to use
Wysong, A., Gladstone, H., Kim, D., Lingala, B., Copeland, J., & Tang, J. Y. (2012). Sunscreen use in NCAA collegiate athletes: Identifying targets for intervention and barriers to use. PREVENTIVE MEDICINE, 55(5), 493–96. -
Is Tanning Bed Exposure Associated With Aggressive Basal Cell Carcinoma?
Gamba, C. A., Wysong, A., Million, L., Aasi, S., Kim, J., & Tang, J. Y. (2012). Is Tanning Bed Exposure Associated With Aggressive Basal Cell Carcinoma? JOURNAL OF CLINICAL ONCOLOGY, 30(32), E333–E336. -
Vitamin D in cutaneous carcinogenesis Part I
Tang, J. Y., Fu, T., Lau, C., Oh, D. H., Bikle, D. D., & Asgari, M. M. (2012). Vitamin D in cutaneous carcinogenesis Part I. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 67(5). -
Vitamin D in cutaneous carcinogenesis: part II.
Tang, J. Y., Fu, T., Lau, C., Oh, D. H., Bikle, D. D., & Asgari, M. M. (2012). Vitamin D in cutaneous carcinogenesis: part II. Journal of the American Academy of Dermatology, 67(5), 817.e1–11; quiz 827–28. -
Does a History of Eczema Predict a Future Basal Cell Carcinoma?
Gamba, C. A., & Tang, J. Y. (2012). Does a History of Eczema Predict a Future Basal Cell Carcinoma? JOURNAL OF INVESTIGATIVE DERMATOLOGY, 132(11), 2497–99. -
Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothened Antagonists
Kim, J., Aftab, B. T., Tang, J. Y., Kim, D., Lee, A. H., Rezaee, M., … Rudin, C. M. (2013). Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothened Antagonists. CANCER CELL, 23(1), 23–34. -
Nonmelanoma Skin Cancer Visits and Procedure Patterns in a Nationally Representative Sample: National Ambulatory Medical Care Survey 1995-2007
Wysong, A., Linos, E., Hernandez-Boussard, T., Arron, S. T., Gladstone, H., & Tang, J. Y. (2013). Nonmelanoma Skin Cancer Visits and Procedure Patterns in a Nationally Representative Sample: National Ambulatory Medical Care Survey 1995-2007. DERMATOLOGIC SURGERY, 39(4), 596–602. -
New Onset of Keratoacanthomas After Vismodegib Treatment for Locally Advanced Basal Cell Carcinomas: A Report of 2 Cases
Aasi, S., Silkiss, R., Tang, J. Y., Wysong, A., Liu, A., Epstein, E., … Chang, A. L. S. (2013). New Onset of Keratoacanthomas After Vismodegib Treatment for Locally Advanced Basal Cell Carcinomas: A Report of 2 Cases. JAMA DERMATOLOGY, 149(2), 242–43. -
Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women The Women's Health Initiative
Gamba, C. A., Swetter, S. M., Stefanick, M. L., Kubo, J., Desai, M., Spaunhurst, K. M., … Tang, J. Y. (2013). Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women The Women's Health Initiative. CANCER, 119(8), 1562–69. -
Cutaneous human papillomavirus infection and Basal cell carcinoma of the skin.
Ally, M. S., Tang, J. Y., & Arron, S. T. (2013). Cutaneous human papillomavirus infection and Basal cell carcinoma of the skin. Journal of Investigative Dermatology, 133(6), 1456–58. -
Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011.
Wysong, A., Aasi, S. Z., & Tang, J. Y. (2013). Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011. JAMA Dermatology , 149(5), 615–616. -
The use of aprepitant in brachioradial pruritus.
Ally, M. S., Gamba, C. S., Peng, D. H., & Tang, J. Y. (2013). The use of aprepitant in brachioradial pruritus. JAMA Dermatology (Chicago, Ill.), 149(5), 627–628. -
Low-Fat Diet and Skin Cancer Risk: The Women's Health Initiative Randomized Controlled Dietary Modification Trial
Gamba, C. S., Stefanick, M. L., Shikany, J. M., Larson, J., Linos, E., Sims, S. T., … Tang, J. Y. (2013). Low-Fat Diet and Skin Cancer Risk: The Women's Health Initiative Randomized Controlled Dietary Modification Trial. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 22(9), 1509–19. -
Role of aspirin and non-aspirin NSAIDs in preventing melanoma.
Ally, M. S., Swetter, S. M., & Tang, J. Y. (2013). Role of aspirin and non-aspirin NSAIDs in preventing melanoma. Future Oncology , 9(11), 1671–74. -
INHIBITION OF LECITHIN-CHOLESTEROL ACYLTRANSFERASE AND MODIFICATION OF HDL APOLIPOPROTEINS BY ALDEHYDES
McCall, M., Tang, J. Y., Bielicki, J. K., & Forte, T. M. (1995). INHIBITION OF LECITHIN-CHOLESTEROL ACYLTRANSFERASE AND MODIFICATION OF HDL APOLIPOPROTEINS BY ALDEHYDES. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 15(10), 1599–1606. -
Lower serum vitamin D levels are associated with increased risk of eczema in US adults
Fu, T., Gamba, C., IVE, H., & Tang, J. Y. (2013). Lower serum vitamin D levels are associated with increased risk of eczema in US adults. Presented at the International Investigative Dermatology Meeting, EDINBURGH,SCOTLAND: NATURE PUBLISHING GROUP. -
Vismodegib as an adjuvant to surgery for basal cell carcinomas
ALLY, M. S., Aasi, S., Chang, A., Teng, C., Anderson, E. M., Bailey, I., … Tang, J. Y. (2013). Vismodegib as an adjuvant to surgery for basal cell carcinomas. Presented at the International Investigative Dermatology Meeting, EDINBURGH,SCOTLAND,SCOTLAND,SCOTLAND,SCOTLAND,SCOTLAND,SCOTLAND,SCOTLAND,SCOTLAND,SCOTLAND,SCOTLAND: NATURE PUBLISHING GROUP. -
Ulcers and stellate scars on bilateral ankles.
Spaunhurst, K. M., Wysong, A., Kim, J., & Tang, J. Y. (2012). Ulcers and stellate scars on bilateral ankles. Archives of Dermatology, 148(3), 385–390. -
Vitamin D in cutaneous carcinogenesis Part II
Tang, J. Y., Fu, T., Lau, C., Oh, D. H., Bikle, D. D., & Asgari, M. M. (2012). Vitamin D in cutaneous carcinogenesis Part II. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 67(5). -
Lower Skin Cancer Risk in Women with Higher Body Mass Index: The Women's Health Initiative Observational Study.
Tang, J. Y., Henderson, M. T., Hernandez-Boussard, T., Kubo, J., Desai, M., Sims, S. T., … Stefanick, M. L. (2013). Lower Skin Cancer Risk in Women with Higher Body Mass Index: The Women's Health Initiative Observational Study. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 22(12), 2412–15. -
Open-Label, Exploratory Phase II Trial of Oral Itraconazole for the Treatment of Basal Cell Carcinoma.
Kim, D. J., Kim, J., Spaunhurst, K., Montoya, J., Khodosh, R., Chandra, K., … Tang, J. Y. (2014). Open-Label, Exploratory Phase II Trial of Oral Itraconazole for the Treatment of Basal Cell Carcinoma. Journal of Clinical Oncology , 32(8), 745–51. -
Network geometry shows evidence sequestration for medical vs. surgical practices: treatments for basal cell carcinoma.
Kim, D. D., Tang, J. Y., & Ioannidis, J. P. A. (2014). Network geometry shows evidence sequestration for medical vs. surgical practices: treatments for basal cell carcinoma. Journal of Clinical Epidemiology, 67(4), 391–400. -
Eczema and sensitization to common allergens in the United States: a multiethnic, population-based study.
Fu, T., Keiser, E., Linos, E., Rotatori, R. M., Sainani, K., Lingala, B., … Tang, J. Y. (2014). Eczema and sensitization to common allergens in the United States: a multiethnic, population-based study. Pediatric Dermatology, 31(1), 21–26. -
Alcohol consumption and risk of melanoma and non-melanoma skin cancer in the Women's Health Initiative
Kubo, J. T., Henderson, M. T., Desai, M., Wactawski-Wende, J., Stefanick, M. L., & Tang, J. Y. (2014). Alcohol consumption and risk of melanoma and non-melanoma skin cancer in the Women's Health Initiative. CANCER CAUSES & CONTROL, 25(1), 1–10. -
Quantifying Soft Tissue Loss in Facial Aging: A Study in Women Using Magnetic Resonance Imaging
Wysong, A., Joseph, T., Kim, D., Tang, J. Y., & Gladstone, H. B. (2013). Quantifying Soft Tissue Loss in Facial Aging: A Study in Women Using Magnetic Resonance Imaging. DERMATOLOGIC SURGERY, 39(12), 1895–1902. -
Lack of efficacy with 1064-nm neodymium:yttrium-aluminum-garnet laser for theÌýtreatment of onychomycosis: A randomized, controlled trial.
Hollmig, S. T., Rahman, Z., Henderson, M. T., Rotatori, R. M., Gladstone, H., & Tang, J. Y. (2014). Lack of efficacy with 1064-nm neodymium:yttrium-aluminum-garnet laser for theÌýtreatment of onychomycosis: A randomized, controlled trial. Journal of the American Academy of Dermatology, 70(5), 911–17. -
Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition.
Tang, Y., Gholamin, S., Schubert, S., Willardson, M. I., Lee, A., Bandopadhayay, P., … Cho, Y.-J. (2014). Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nature Medicine, 20(7), 732–40. -
The use of vismodegib to shrink keratocystic odontogenic tumors in patients with Basal cell nevus syndrome.
Ally, M. S., Tang, J. Y., Joseph, T., Thompson, B., Lindgren, J., Raphael, M. A., … Epstein, E. H. (2014). The use of vismodegib to shrink keratocystic odontogenic tumors in patients with Basal cell nevus syndrome. JAMA Dermatology, 150(5), 542–45. -
Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for Basal cell carcinoma prevention and therapy in patients with Basal cell nevus syndrome.
Tang, J. Y., Chiou, A. S., Mackay-Wiggan, J. M., Aszterbaum, M., Chanana, A. M., Lee, W., … Epstein, E. H. (2014). Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for Basal cell carcinoma prevention and therapy in patients with Basal cell nevus syndrome. Cancer Prevention Research , 7(3), 292–99. -
Epigenetic targeting of hedgehog pathway transcriptional output.
Cho, Y.-J. J., Tang, Y., Schubert, S., Willardson, M., Bandopadhayay, P., Bergthold, G., … Cho, Y.-J. J. (2014). Epigenetic targeting of hedgehog pathway transcriptional output. Neuro-Oncology, 16 Suppl 3, iii25. -
Non-steroidal anti-inflammatory drugs and cancer risk in women: Results from the Women's Health Initiative
Brasky, T. M., Liu, J., White, E., Peters, U., Potter, J. D., Walter, R. B., … Wactawski-Wende, J. (2014). Non-steroidal anti-inflammatory drugs and cancer risk in women: Results from the Women's Health Initiative. INTERNATIONAL JOURNAL OF CANCER, 135(8), 1869–1883. -
Vitamin D levels and menopause-related symptoms.
LeBlanc, E. S., Desai, M., Perrin, N., Wactawski-Wende, J., Manson, J. A. E., Cauley, J. A., … Stefanick, M. L. (2014). Vitamin D levels and menopause-related symptoms. Menopause (New York, N.Y.), 21(11), 1197–1203. -
Automated identification of basal cell carcinoma by polarization-sensitive optical coherence tomography
Duan, L., Marvdashti, T., Lee, A., Tang, J. Y., & Ellerbee, A. K. (2014). Automated identification of basal cell carcinoma by polarization-sensitive optical coherence tomography. BIOMEDICAL OPTICS EXPRESS, 5(10), 3717–29. -
Non-melanoma skin cancer and NSAID use in women with a history of skin cancer in the Women's Health Initiative
Wysong, A., Ally, M. S., Gamba, C. S., Desai, M., Swetter, S. M., Seiffert-Sinha, K., … Tang, J. Y. (2014). Non-melanoma skin cancer and NSAID use in women with a history of skin cancer in the Women's Health Initiative. PREVENTIVE MEDICINE, 69, 8–12. -
Smoothened variants explain the majority of drug resistance in Basal cell carcinoma.
Atwood, S. X., Sarin, K. Y., Whitson, R. J., Li, J. R., Kim, G., Rezaee, M., … Tang, J. Y. (2015). Smoothened variants explain the majority of drug resistance in Basal cell carcinoma. Cancer Cell, 27(3), 342–53. -
Detection of Non-Melanoma Skin Cancer by in vivo Fluorescence Imaging with Fluorocoxib A.
Ra, H., González-González, E., Uddin, M. J., King, B. L., Lee, A., Ali-Khan, I., … Contag, C. H. (2015). Detection of Non-Melanoma Skin Cancer by in vivo Fluorescence Imaging with Fluorocoxib A. Neoplasia , 17(2), 201–7. -
Smoking behavior and association of melanoma and nonmelanoma skin cancer in the Women's Health Initiative
Henderson, M. T., Kubo, J. T., Desai, M., David, S. P., Tindle, H., Sinha, A. A., … Tang, J. Y. (2015). Smoking behavior and association of melanoma and nonmelanoma skin cancer in the Women's Health Initiative. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 72(1), 190–191. -
Genomic analysis of smoothened inhibitor resistance in Basal cell carcinoma.
Sharpe, H. J., Pau, G., Dijkgraaf, G. J., Basset-Seguin, N., Modrusan, Z., Januario, T., … de Sauvage, F. J. (2015). Genomic analysis of smoothened inhibitor resistance in Basal cell carcinoma. Cancer Cell, 27(3), 327–41. -
Rolling the Genetic Dice: Neutral and Deleterious Smoothened Mutations in Drug-Resistant Basal Cell Carcinoma.
Atwood, S. X., Sarin, K. Y., Li, J. R., Yao, C. Y., Urman, N. M., Chang, A. L. S., … Oro, A. E. (2015). Rolling the Genetic Dice: Neutral and Deleterious Smoothened Mutations in Drug-Resistant Basal Cell Carcinoma. Journal of Investigative Dermatology, 135(8), 2138–41. -
Dermatologic applications of direct-to-consumer genomic analysis.
Fogel, A. L., Azizi, N., Tang, J., & Sarin, K. Y. (2014). Dermatologic applications of direct-to-consumer genomic analysis. Journal of the American Academy of Dermatology, 71(5), 993–95. -
An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
Ally, M. S., Aasi, S., Wysong, A., Teng, C., Anderson, E., Bailey-Healy, I., … Tang, J. Y. (2014). An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. Journal of the American Academy of Dermatology, 71(5), 904–11 e1. -
Pilot study on the bioactivity of vitamin d in the skin after oral supplementation.
Curiel-Lewandrowski, C., Tang, J. Y., Einspahr, J. G., Bermudez, Y., Hsu, C. H., Rezaee, M., … Chow, H.-H. S. (2015). Pilot study on the bioactivity of vitamin d in the skin after oral supplementation. Cancer Prevention Research , 8(6), 563–69. -
Squamous Change in Basal-Cell Carcinoma with Drug Resistance.
Ransohoff, K. J., Tang, J. Y., & Sarin, K. Y. (2015). Squamous Change in Basal-Cell Carcinoma with Drug Resistance. New England Journal of Medicine, 373(11), 1079–82. -
Mutations in the Kinetochore Gene KNSTRN in Basal Cell Carcinoma.
Jaju, P. D., Nguyen, C. B., Mah, A. M., Atwood, S. X., Li, J., Zia, A., … Sarin, K. Y. (2015). Mutations in the Kinetochore Gene KNSTRN in Basal Cell Carcinoma. Journal of Investigative Dermatology, 135(12), 3197–3200. -
Smoothened Inhibitors in Sonic Hedgehog Subgroup Medulloblastoma.
Ransohoff, K. J., Sarin, K. Y., & Tang, J. Y. (2015). Smoothened Inhibitors in Sonic Hedgehog Subgroup Medulloblastoma. Journal of Clinical Oncology , 33(24), 2692–94. -
Effect of Calcium Channel Blockade on Vismodegib-Induced Muscle Cramps.
Ally, M. S., Tang, J. Y., Lindgren, J., Acosta-Raphael, M., Rezaee, M., Chanana, A. M., & Epstein, E. H. (2015). Effect of Calcium Channel Blockade on Vismodegib-Induced Muscle Cramps. JAMA Dermatology, 151(10), 1132–34. -
Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma.
Ally, M. S., Ransohoff, K., Sarin, K., Atwood, S. X., Rezaee, M., Bailey-Healy, I., … Colevas, A. D. (2016). Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma. JAMA Dermatology, 152(4), 452–56. -
Effects of combined treatment with arsenic trioxide and itraconazole in patients with refractory metastatic basal cell carcinoma
Sarin, K. Y., Ally, M. S., Ransohoff, K. J., Atwood, S. X., & Rezaee, M. (2016). Effects of combined treatment with arsenic trioxide and itraconazole in patients with refractory metastatic basal cell carcinoma. JAMA Dermatology, 1–5. -
Familial skin cancer syndromes Increased melanoma risk
Ransohoff, K. J., Jaju, P. D., Tang, J. Y., Carbone, M., Leachman, S., & Sarin, K. Y. (2016). Familial skin cancer syndromes Increased melanoma risk. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 74(3), 423–34. -
Familial skin cancer syndromes Increased risk of nonmelanotic skin cancers and extracutaneous tumors
Jaju, P. D., Ransohoff, K. J., Tang, J. Y., & Sarin, K. Y. (2016). Familial skin cancer syndromes Increased risk of nonmelanotic skin cancers and extracutaneous tumors. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 74(3), 437–51. -
Relation of statin use with non-melanoma skin cancer: prospective results from the Women's Health Initiative.
Wang, A., Stefanick, M. L., Kapphahn, K., Hedlin, H., Desai, M., Manson, J. A. E., … Tang, J. Y. (2016). Relation of statin use with non-melanoma skin cancer: prospective results from the Women's Health Initiative. British Journal of Cancer, 114(3), 314–20. -
Impact of residential UV exposure in childhood versus adulthood on skin cancer risk in Caucasian, postmenopausal women in the Women's Health Initiative
Ransohoff, K. J., Ally, M. S., Stefanick, M. L., Keiser, E., Spaunhurst, K., Kapphahn, K., … Tang, J. Y. (2016). Impact of residential UV exposure in childhood versus adulthood on skin cancer risk in Caucasian, postmenopausal women in the Women's Health Initiative. CANCER CAUSES & CONTROL, 27(6), 817–23. -
Statin use and all-cancer survival: prospective results from the Women's Health Initiative
Wang, A., Aragaki, A. K., Tang, J. Y., Kurian, A. W., Manson, J. A. E., Chlebowski, R. T., … Stefanick, M. L. (2016). Statin use and all-cancer survival: prospective results from the Women's Health Initiative. BRITISH JOURNAL OF CANCER, 115(1), 129–35. -
Genome-wide association study identifies 14 novel risk alleles associated with basal cell carcinoma.
Chahal, H. S., Wu, W., Ransohoff, K. J., Yang, L., Hedlin, H., Desai, M., … Sarin, K. Y. (2016). Genome-wide association study identifies 14 novel risk alleles associated with basal cell carcinoma. Nature Communications, 7, 12510-? -
Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma
Chen, B., Vinh Trang, V., Lee, A., Williams, N. S., Wilson, A. N., Epstein, E. H., … Kim, J. (2016). Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma. MOLECULAR CANCER THERAPEUTICS, 15(5), 866–76. -
Genome-wide association study identifies novel susceptibility loci for cutaneous squamous cell carcinoma.
Chahal, H. S., Lin, Y., Ransohoff, K. J., Hinds, D. A., Wu, W., Dai, H.-ji, … Sarin, K. Y. (2016). Genome-wide association study identifies novel susceptibility loci for cutaneous squamous cell carcinoma. Nature Communications, 7, 12048-? -
Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients?
Wang, A., Wakelee, H. A., Aragaki, A. K., Tang, J. Y., Kurian, A. W., Manson, J. A. E., & Stefanick, M. L. (2016). Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients? Current Atherosclerosis Reports, 18(12), 72-? -
Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Tang, J. Y., Ally, M. S., Chanana, A. M., Mackay-Wiggan, J. M., Aszterbaum, M., Lindgren, J. A., … Epstein, E. H. (2016). Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. LANCET ONCOLOGY, 17(12), 1720–31. -
Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa.
Siprashvili, Z., Nguyen, N. T., Gorell, E. S., Loutit, K., Khuu, P., Furukawa, L. K., … Marinkovich, M. P. (2016). Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa. JAMA, 316(17), 1808–17. -
GLI activation by atypical protein kinase C iota/lambda regulates the growth of basal cell carcinomas
Atwood, S. X., Li, M., Lee, A., Tang, J. Y., & Oro, A. E. (2013). GLI activation by atypical protein kinase C iota/lambda regulates the growth of basal cell carcinomas. NATURE, 494(7438), 484–88. -
Classification of basal cell carcinoma in human skin using machine learning and quantitative features captured by polarization sensitive optical coherence tomography.
Marvdashti, T., Duan, L., Aasi, S. Z., Tang, J. Y., & Ellerbee Bowden, A. K. (2016). Classification of basal cell carcinoma in human skin using machine learning and quantitative features captured by polarization sensitive optical coherence tomography. Biomedical Optics Express, 7(9), 3721–35. -
Tumor-Derived Suppressor of Fused Mutations Reveal Hedgehog Pathway Interactions
Urman, N. M., Mirza, A., Atwood, S. X., Whitson, R. J., Sarin, K. Y., Tang, J. Y., & Oro, A. E. (2016). Tumor-Derived Suppressor of Fused Mutations Reveal Hedgehog Pathway Interactions. PLOS ONE, 11(12). -
Factors influencing and modifying the decision to pursue genetic testing for skin cancer risk.
Fogel, A. L., Jaju, P. D., Li, S., Halpern-Felsher, B., Tang, J. Y., & Sarin, K. Y. (2017). Factors influencing and modifying the decision to pursue genetic testing for skin cancer risk. Journal of the American Academy of Dermatology. -
Association between genetic variation within vitamin D receptor-DNA binding sites and risk of basal cell carcinoma.
Lin, Y., Chahal, H. S., Wu, W., Cho, H. G., Ransohoff, K. J., Dai, H., … Han, J. (2017). Association between genetic variation within vitamin D receptor-DNA binding sites and risk of basal cell carcinoma. International Journal of Cancer. -
Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.
Ransohoff, K. J., Wu, W., Cho, H. G., Chahal, H. C., Lin, Y., Dai, H.-ji, … Sarin, K. Y. (2017). Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma. Oncotarget. -
Risk Factors for Basal Cell Carcinoma Among Patients With Basal Cell Nevus Syndrome Development of a Basal Cell Nevus Syndrome Patient Registry
Solis, D. C., Kwon, G. P., Ransohoff, K. J., Li, S., Chahal, H. S., Ally, M. S., … Tang, J. Y. (2017). Risk Factors for Basal Cell Carcinoma Among Patients With Basal Cell Nevus Syndrome Development of a Basal Cell Nevus Syndrome Patient Registry. JAMA DERMATOLOGY, 153(2), 189–92. -
Correlates of multiple basal cell carcinoma in a retrospective cohort study: Sex, histologic subtypes, and anatomic distribution.
Kuo, K. Y., Batra, P., Cho, H. G., Li, S., Chahal, H. S., Rieger, K. E., … Sarin, K. Y. (2017). Correlates of multiple basal cell carcinoma in a retrospective cohort study: Sex, histologic subtypes, and anatomic distribution. Journal of the American Academy of Dermatology. -
Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment.
Mirza, A. N., Fry, M. A., Urman, N. M., Atwood, S. X., Roffey, J., Ott, G. R., … Oro, A. E. (2017). Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment. JCI Insight, 2(21). -
Genomic Stability in Syndromic Basal Cell Carcinoma.
Chiang, A., Jaju, P. D., Batra, P., Rezaee, M., Epstein, E. H., Tang, J. Y., & Sarin, K. Y. (2017). Genomic Stability in Syndromic Basal Cell Carcinoma. The Journal of Investigative Dermatology. -
Noncanonical hedgehog pathway activation through SRF-MKL1 promotes drug resistance in basal cell carcinomas.
Whitson, R. J., Lee, A., Urman, N. M., Mirza, A., Yao, C. Y., Brown, A. S., … Oro, A. E. (2018). Noncanonical hedgehog pathway activation through SRF-MKL1 promotes drug resistance in basal cell carcinomas. Nature Medicine, 24(3), 271–81. -
Validity and Accuracy of a Mobile Phone Application for the Assessment of Wounds in Recessive Dystrophic Epidermolysis Bullosa.
Nazaroff, J., Solis, D., Barriga, M., Dutt-Singkh, Y., Shufeng, L., Marinkovich, M. P., & Tang, J. Y. (2017). Validity and Accuracy of a Mobile Phone Application for the Assessment of Wounds in Recessive Dystrophic Epidermolysis Bullosa. Journal of the American Academy of Dermatology. -
OVERCOMING ACQUIRED AND A PRIORI RESISTANCE TO SMO ANTAGONISTS THROUGH EPIGENETIC REGULATION OF HEDGEHOG PATHWAY TRANSCRIPTIONAL OUTPUT
Tang, Y., Schubert, S., Brian Nguyen, Masoud, S., Gholamin, S., Lee, A., … Cho, Y.-J. (2014). OVERCOMING ACQUIRED AND A PRIORI RESISTANCE TO SMO ANTAGONISTS THROUGH EPIGENETIC REGULATION OF HEDGEHOG PATHWAY TRANSCRIPTIONAL OUTPUT. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC. -
Neuronal delivery of Hedgehog directs spatial patterning of taste organ regeneration.
Lu, W.-J. J., Mann, R. K., Nguyen, A., Bi, T., Silverstein, M., Tang, J. Y., … Beachy, P. A. (2018). Neuronal delivery of Hedgehog directs spatial patterning of taste organ regeneration. Proceedings of the National Academy of Sciences of the United States of America, 115(2), E200–E209. -
Melanoma risk prediction using a multilocus genetic risk score in the Women's Health Initiative cohort.
Cho, H. G., Ransohoff, K. J., Yang, L., Hedlin, H., Assimes, T., Han, J., … Sarin, K. Y. (2018). Melanoma risk prediction using a multilocus genetic risk score in the Women's Health Initiative cohort. Journal of the American Academy of Dermatology. -
Natural history of lesions suspicious for basal cell carcinoma in older adults in Ikaria, Greece.
Wehner, M. R., Dalma, N., Landefeld, C., Pare-Anastasiadou, A., Koutelidas, I., Chren, M. M., … Linos, E. (2018). Natural history of lesions suspicious for basal cell carcinoma in older adults in Ikaria, Greece. The British Journal of Dermatology. -
Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial
Yosipovitch, G., Stander, S., Kerby, M. B., Larrick, J. W., Perlman, A. J., Schnipper, E. F., … Steinhoff, M. (2018). Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 78(5), 882-+. -
Azathioprine and risk of multiple keratinocyte cancers.
Cho, H. G., Kuo, K. Y., Xiao, K., Batra, P., Li, S., Tang, J. Y., & Sarin, K. Y. (2018). Azathioprine and risk of multiple keratinocyte cancers. Journal of the American Academy of Dermatology, 78(1), 27–28.e1. -
Distinguishing malignant from benign microscopic skin lesions using desorption electrospray ionization mass spectrometry imaging.
Margulis, K., Chiou, A. S., Aasi, S. Z., Tibshirani, R. J., Tang, J. Y., & Zare, R. N. (2018). Distinguishing malignant from benign microscopic skin lesions using desorption electrospray ionization mass spectrometry imaging. Proceedings of the National Academy of Sciences of the United States of America. -
Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes
Ko, J. S., Matharoo-Ball, B., Billings, S. D., Thomson, B. J., Tang, J. Y., Sarin, K. Y., … Clarke, L. E. (2017). Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 26(7), 1107–13. -
Statin use and non-melanoma skin cancer risk: a meta-analysis of randomized controlled trials and observational studies
Yang, K., Marley, A., Tang, H., Song, Y., Tang, J. Y., & Han, J. (2017). Statin use and non-melanoma skin cancer risk: a meta-analysis of randomized controlled trials and observational studies. ONCOTARGET, 8(43), 75411–17. -
Association of 25-hydroxyvitamin D levels and cutaneous melanoma: A nested case-control study of the Women's Health Initiative Observation Study.
Kwon, G. P., Gamba, C. S., Stefanick, M. L., Swetter, S. M., Li, S., Shi, R. Z., … Tang, J. Y. (2018). Association of 25-hydroxyvitamin D levels and cutaneous melanoma: A nested case-control study of the Women's Health Initiative Observation Study. Journal of the American Academy of Dermatology, 79(1), 145–47. -
Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.
Shkolyar, E., Li, S., Tang, J., & Eisenberg, M. L. (2018). Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms. The Journal of Sexual Medicine. -
Towards automated detection of basal cell carcinoma from polarization sensitive optical coherence tomography images of human skin
Marvdashti, T., Duan, L., Ransohoff, K. J., Aasi, S. Z., Tang, J. Y., & Ellerbee, A. K. (2015). Towards automated detection of basal cell carcinoma from polarization sensitive optical coherence tomography images of human skin. 2015 CONFERENCE ON LASERS AND ELECTRO-OPTICS (CLEO). -
Measurement of Skin Adhesion in Recessive Dystrophic Epidermolysis Bullosa Patients.
Nazaroff, J., Manoukian, M., Barriga, M., Lane, A., Marinkovich, M. P., & Tang, J. Y. (2018). Measurement of Skin Adhesion in Recessive Dystrophic Epidermolysis Bullosa Patients. Journal of the American Academy of Dermatology. -
Frequent basal cell cancer development is a clinical marker for inherited cancer susceptibility
Cho, H. G., Kuo, K. Y., Li, S., Bailey, I., Aasi, S., Chang, A. L. S., … Sarin, K. Y. (2018). Frequent basal cell cancer development is a clinical marker for inherited cancer susceptibility. JCI INSIGHT, 3(15). -
Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience
Cornetta, K., Duffy, L., Feldman, S. A., Mackall, C. L., Davila, M. L., Curran, K. J., … Rosenberg, S. A. (2018). Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience. MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 10, 371–78. -
Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America.
Feinstein, J. A., Jambal, P., Peoples, K., Lucky, A. W., Khuu, P., Tang, J. Y., … Bruckner, A. L. (2018). Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America. JAMA Dermatology. -
An investigator-initiated, phase II randomized, double-blind, placebo controlled trial of GDC-0449 for prevention of BCCs in basal cell nevus syndrome (BCNS) patients.gg
Tang, J. Y., Mackay-Wiggan, J. M., Aszterbaum, M., Lindgren, J., Chang, K., Coppola, C., … Epstein, E. H. (2011). An investigator-initiated, phase II randomized, double-blind, placebo controlled trial of GDC-0449 for prevention of BCCs in basal cell nevus syndrome (BCNS) patients.gg. CANCER RESEARCH, 71. -
Preliminary effectiveness and safety in the first 88 patients with newly diagnosed locally advanced basal cell carcinoma treated with vismodegib in the RegiSONIC Disease Registry study
Lacouture, M. E., Tang, J. Y., Rogers, G., Olencki, T., Kudchadkar, R. R., Yoo, S., … Sekulic, A. (2016). Preliminary effectiveness and safety in the first 88 patients with newly diagnosed locally advanced basal cell carcinoma treated with vismodegib in the RegiSONIC Disease Registry study. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 74(5), AB202. -
Management of common vismodegib (VISMO)-related adverse events in patients with locally advanced basal cell carcinoma (laBCC): RegiSONIC Disease Registry Study
Lacouture, M. E., Guillen, J., Kudchadkar, R., Rogers, G., Olencki, T., Tang, J., … Sekulic, A. (2016). Management of common vismodegib (VISMO)-related adverse events in patients with locally advanced basal cell carcinoma (laBCC): RegiSONIC Disease Registry Study. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 74(5), AB200. -
Height, height-related SNPs, and risk of non-melanoma skin cancer
Li, X., Liang, L., Feng, Y.-C. A., De Vivo, I., Giovannucci, E., Tang, J. Y., & Han, J. (2017). Height, height-related SNPs, and risk of non-melanoma skin cancer. BRITISH JOURNAL OF CANCER, 116(1), 134–40. -
A genome-wide analysis of gene-caffeine consumption interaction on basal cell carcinoma
Li, X., Cornelis, M. C., Liang, L., Song, F., De Vivo, I., Giovannucci, E., … Han, J. (2016). A genome-wide analysis of gene-caffeine consumption interaction on basal cell carcinoma. CARCINOGENESIS, 37(12), 1138–43. -
Nanoelectroablation therapy for murine basal cell carcinoma (vol 424, pg 446, 2012)
Nuccitelli, R., Tran, K., Athos, B., Kreis, M., Nuccitelli, P., Chang, K. S., … Tang, J. Y. (2016). Nanoelectroablation therapy for murine basal cell carcinoma (vol 424, pg 446, 2012). BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 480(2), 288. -
Pre-diagnostic leukocyte mitochondrial DNA copy number and skin cancer risk
Meng, S., De Vivo, I., Liang, L., Giovannucci, E., Tang, J. Y., & Han, J. (2016). Pre-diagnostic leukocyte mitochondrial DNA copy number and skin cancer risk. CARCINOGENESIS, 37(9), 897–903. -
Pathway analysis of expression-related SNPs on genome-wide association study of basal cell carcinoma
Li, X., Liang, L., De Vivo, I., Tang, J. Y., & Han, J. (2016). Pathway analysis of expression-related SNPs on genome-wide association study of basal cell carcinoma. ONCOTARGET, 7(24), 36885–95. -
Determination of locally advanced basal cell carcinoma (BCC) in the first 285 patients enrolled in the RegiSONIC disease registry study.
Yoo, S. S., Tang, J. Y., Rogers, G. S., Olencki, T., Lacouture, M. E., Kudchadkar, R. R., … Sekulic, A. (2015). Determination of locally advanced basal cell carcinoma (BCC) in the first 285 patients enrolled in the RegiSONIC disease registry study. JOURNAL OF CLINICAL ONCOLOGY, 33(15). -
Vismodegib in Advanced Basal-Cell Carcinoma Reply
Epstein, E. H., Tang, J. Y., & Bickers, D. R. (2012). Vismodegib in Advanced Basal-Cell Carcinoma Reply. NEW ENGLAND JOURNAL OF MEDICINE, 367(10), 970–71. -
Melanoma risk prediction using a multilocus genetic risk score in the Women's Health Initiative cohort
Cho, H. G., Ransohoff, K. J., Yang, L., Hedlin, H., Assimes, T., Han, J., … Sarin, K. Y. (2018). Melanoma risk prediction using a multilocus genetic risk score in the Women's Health Initiative cohort. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 79(1), 36-+. -
Gene Therapy for Epidermolysis Bullosa
Marinkovich, M. P., & Tang, J. Y. (2019). Gene Therapy for Epidermolysis Bullosa. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 139(6), 1221–26. -
Genetic Mutations Underlying Phenotypic Plasticity in Basosquamous Carcinoma
Chiang, A., Tan, C. Z., Kuonen, F., Hodgkinson, L. M., Chiang, F., Cho, R. J., … Sarin, K. Y. (2019). Genetic Mutations Underlying Phenotypic Plasticity in Basosquamous Carcinoma. Journal of INVESTIGATIVE DERMATOLOGY | Original Article | Carcinogenesis/Tumorigenesis, 139(11). -
Topical Itraconazole for the Treatment of Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome or High-Frequency Basal Cell Carcinomas: A Phase 2, Open-Label, Placebo-Controlled Trial.
Sohn, G. K., Kwon, G. P., Bailey-Healy, I., Mirza, A., Sarin, K., Oro, A., & Tang, J. Y. (2019). Topical Itraconazole for the Treatment of Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome or High-Frequency Basal Cell Carcinomas: A Phase 2, Open-Label, Placebo-Controlled Trial. JAMA Dermatology. -
Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America
Feinstein, J. A., Jambal, P., Peoples, K., Lucky, A. W., Phuong Khuu, Tang, J. Y., … Bruckner, A. L. (2019). Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America. JAMA DERMATOLOGY, 155(2), 196–203. -
Phase 2 Trial of a Neurokinin-1 Receptor Antagonist for the Treatment of Chronic Itch in Epidermolysis Bullosa Patients: A Randomized Clinical Trial.
Chiou, A. S., Choi, S., Barriga, M., Dutt-Singkh, Y., Solis, D. C., Nazaroff, J., … Tang, J. Y. (2019). Phase 2 Trial of a Neurokinin-1 Receptor Antagonist for the Treatment of Chronic Itch in Epidermolysis Bullosa Patients: A Randomized Clinical Trial. Journal of the American Academy of Dermatology. -
Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa.
Eichstadt, S., Barriga, M., Ponakala, A., Teng, C., Nguyen, N. T., Siprashvili, Z., … Tang, J. Y. (2019). Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa. JCI Insight, 4(19). -
Prevalence and penetrance of breast cancer-associated mutations identified by multiple-gene sequencing in the Women's Health Initiative.
Kurian, A. W., Hughes, E., Bernhisel, R., Larson, K., Caswell-Jin, J. L., Shadyab, A. H., … Stefanick, M. L. (2019). Prevalence and penetrance of breast cancer-associated mutations identified by multiple-gene sequencing in the Women's Health Initiative. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
From Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Eichstadt, S., Tang, J. Y., Solis, D. C., Siprashvili, Z., Marinkovich, M. P., Whitehead, N., … Sarin, K. Y. (2019). From Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB). CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 12, 933–42. -
From Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB).
Eichstadt, S., Tang, J. Y., Solis, D. C., Siprashvili, Z., Marinkovich, M. P., Whitehead, N., … Sarin, K. Y. (2019). From Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB). Clinical, Cosmetic and Investigational Dermatology, 12, 933–942. -
Patient Reported Outcomes and Quality of Life in Recessive Dystrophic Epidermolysis Bullosa: A Global Cross-sectional Survey.
Eng, V. A., Solis, D. C., Gorell, E. S., Choi, S., Nazaroff, J., Li, S., … Tang, J. Y. (2020). Patient Reported Outcomes and Quality of Life in Recessive Dystrophic Epidermolysis Bullosa: A Global Cross-sectional Survey. Journal of the American Academy of Dermatology. -
Multidisciplinary Care of Epidermolysis Bullosa during the COVID-19 Pandemic - Consensus: Recommendations by an International Panel of Experts.
Murrell, D. F., Lucky, A. W., Salas-Alanis, J. C., Woodley, D. T., Palisson, F., Natsuga, K., … Martinez, A. E. (2020). Multidisciplinary Care of Epidermolysis Bullosa during the COVID-19 Pandemic - Consensus: Recommendations by an International Panel of Experts. Journal of the American Academy of Dermatology. -
Prevalence and risk factors for high frequency basal cell carcinoma in the United States.
Chiang, A., Solis, D. C., Rogers, H., Sohn, G. K., Cho, H. G., Saldanha, G., … Tang, J. Y. (2020). Prevalence and risk factors for high frequency basal cell carcinoma in the United States. Journal of the American Academy of Dermatology. -
The association between cigarette smoking, cancer screening, and cancer stage: a prospective study of the women's health initiative observational cohort.
Eng, V. A., David, S. P., Li, S., Ally, M. S., Stefanick, M., & Tang, J. Y. (2020). The association between cigarette smoking, cancer screening, and cancer stage: a prospective study of the women's health initiative observational cohort. BMJ Open, 10(8), e037945. -
Induced Remission of Metastatic Squamous Cell Carcinoma with an Immune Checkpoint Inhibitor in a Patient with Recessive Dystrophic Epidermolysis Bullosa.
Khaddour, K., Gorell, E. S., Dehdashti, F., Tang, J. Y., & Ansstas, G. (2020). Induced Remission of Metastatic Squamous Cell Carcinoma with an Immune Checkpoint Inhibitor in a Patient with Recessive Dystrophic Epidermolysis Bullosa. Case Reports in Oncology, 13(2), 911–15. -
Classification of Two Distinct Wound Types in Recessive Dystrophic Epidermolysis Bullosa: A Retrospective and Cohort Natural History Study.
Solis, D. C., Teng, C., Gorell, E. S., Barriga, M., Nazaroff, J., Li, S., … Tang, J. Y. (2020). Classification of Two Distinct Wound Types in Recessive Dystrophic Epidermolysis Bullosa: A Retrospective and Cohort Natural History Study. Journal of the American Academy of Dermatology. -
Financial burden of epidermolysis bullosa on patients in the United States.
Gorell, E. S., Wolstencroft, P. W., de Souza, M. P., Murrell, D. F., Linos, E., & Tang, J. Y. (2020). Financial burden of epidermolysis bullosa on patients in the United States. Pediatric Dermatology. -
CLASSIFICATION OF TWO DISTINCT WOUND TYPES IN RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA: A NATURAL HISTORY STUDY
Teng, C. E., Solis, D. C., Barriga, M., Li, S., Marinkovich, M. P., & Tang, J. Y. (2020). CLASSIFICATION OF TWO DISTINCT WOUND TYPES IN RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA: A NATURAL HISTORY STUDY. ACTA DERMATO-VENEREOLOGICA. ACTA DERMATO-VENEREOLOGICA. -
Hedgehog pathway inhibition by topical patidegib to reduce BCC burden in patients with basal cell nevus (Gorlin) syndrome.
Epstein, E. H., Lear, J., Saldanha, G., Tang, J. Y., & Harwood, C. (2018). Hedgehog pathway inhibition by topical patidegib to reduce BCC burden in patients with basal cell nevus (Gorlin) syndrome. JOURNAL OF CLINICAL ONCOLOGY, 36(15). -
Direct-to-Consumer Genetic Risk Scoring for Melanoma Improves Adherence to Sun-Protective Behaviors Among Increased-Risk Groups: Results from a Prospective U.S. Cohort Study.
Hu, X., Kilgour, J. M., Fogel, A. L., Jia, J. L., Jaju, P. D., Tang, J. Y., & Sarin, K. Y. (2021). Direct-to-Consumer Genetic Risk Scoring for Melanoma Improves Adherence to Sun-Protective Behaviors Among Increased-Risk Groups: Results from a Prospective U.S. Cohort Study. Journal of the American Academy of Dermatology. -
Clinical characteristics associated with increased wound size in patients with recessive dystrophic epidermolysis bullosa.
Solis, D. C., Gorell, E. S., Teng, C., Barriga, M., Nazaroff, J., Li, S., … Tang, J. Y. (2021). Clinical characteristics associated with increased wound size in patients with recessive dystrophic epidermolysis bullosa. Pediatric Dermatology. -
A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa.
Tang, J. Y., Marinkovich, M. P., Lucas, E., Gorell, E., Chiou, A., Lu, Y., … Rudin, D. (2021). A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa. Orphanet Journal of Rare Diseases, 16(1), 175. -
Measurement of skin adhesion in recessive dystrophic epidermolysis bullosa patients
Nazaroff, J., Manoukian, M., Barriga, M., Lane, A., Marinkovich, M. P., & Tang, J. Y. (2021). Measurement of skin adhesion in recessive dystrophic epidermolysis bullosa patients. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 85(2), 491–492. -
Validity and accuracy of a mobile phone application for the assessment of wounds in recessive dystrophic epidermolysis bullosa
Nazaroff, J., Solis, D., Barriga, M., Dutt-Singkh, Y., Li, S., Marinkovich, P. M., & Tang, J. Y. (2021). Validity and accuracy of a mobile phone application for the assessment of wounds in recessive dystrophic epidermolysis bullosa. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 85(2), 468–469. -
Cannabinoid use and effects in patients with epidermolysis bullosa: an international cross-sectional survey study.
Schrader, N. H., Gorell, E. S., Stewart, R. E., Duipmans, J. C., Harris, N., Perez, V. A., … Bolling, M. C. (2021). Cannabinoid use and effects in patients with epidermolysis bullosa: an international cross-sectional survey study. Orphanet Journal of Rare Diseases, 16(1), 377. -
Patient-reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global cross-sectional survey.
Fulchand, S., Harris, N., Li, S., Barriga, M., Gorell, E., De Souza, M., … Tang, J. Y. (2021). Patient-reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global cross-sectional survey. Pediatric Dermatology. -
A retrospective analysis of diagnostic testing in a large North American cohort of patients with epidermolysis bullosa.
Phillips, G. S., Huang, A., Augsburger, B. D., Kaplan, L., Peoples, K., Bruckner, A. L., … Glick, S. A. (2021). A retrospective analysis of diagnostic testing in a large North American cohort of patients with epidermolysis bullosa. Journal of the American Academy of Dermatology. -
Gorlin Syndrome: Assessing Genotype-Phenotype Correlations and Analysis of Early Clinical Characteristics as Risk Factors for Disease Severity.
Betancourt, N. J., Qian, M. F., Pickford, J. R., Bailey-Healy, I., Tang, J. Y., & Teng, J. M. (2022). Gorlin Syndrome: Assessing Genotype-Phenotype Correlations and Analysis of Early Clinical Characteristics as Risk Factors for Disease Severity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2102385. -
A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex.
So, J. Y., Fulchand, S., Wong, C. Y., Li, S., Nazaroff, J., Gorell, E. S., … Tang, J. Y. (2022). A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex. Orphanet Journal of Rare Diseases, 17(1), 270. -
Asymptomatic, Microscopic Hematuria in Epidermolysis Bullosa: A Single Center Retrospective Case Series.
Betancourt, N. J., Sum, K., Gorell, E. S., Tang, J. Y., & Chiou, A. S. (2022). Asymptomatic, Microscopic Hematuria in Epidermolysis Bullosa: A Single Center Retrospective Case Series. Journal of the American Academy of Dermatology. -
Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa.
So, J. Y., Nazaroff, J., Iwummadu, C. V., Harris, N., Gorell, E. S., Fulchand, S., … Chiou, A. S. (2022). Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa. Orphanet Journal of Rare Diseases, 17(1), 377. -
LY6D marks pre-existing resistant basosquamous tumor subpopulations.
Haensel, D., Gaddam, S., Li, N. Y., Gonzalez, F., Patel, T., Cloutier, J. M., … Oro, A. E. (2022). LY6D marks pre-existing resistant basosquamous tumor subpopulations. Nature Communications, 13(1), 7520. -
Advances in cutaneous squamous cell carcinoma.
Winge, M. C., Kellman, L. N., Guo, K., Tang, J. Y., Swetter, S. M., Aasi, S. Z., … Khavari, P. A. (2023). Advances in cutaneous squamous cell carcinoma. Nature Reviews. Cancer. -
Development of a digital tool for home-based monitoring of skin disease for older adults.
van Egmond, S., Cai, Z. R., Nava, V., Joy de Vere Hunt, I., Rapaport, B. R., Ko, J., … Linos, E. (2023). Development of a digital tool for home-based monitoring of skin disease for older adults. Skin Health and Disease, 3(5), e235. -
A scalable, GMP-compatible, autologous organotypic cell therapy for Dystrophic Epidermolysis Bullosa.
Neumayer, G., Torkelson, J. L., Li, S., McCarthy, K., Zhen, H. H., Vangipuram, M., … Oro, A. E. (2023). A scalable, GMP-compatible, autologous organotypic cell therapy for Dystrophic Epidermolysis Bullosa. BioRxiv : the Preprint Server for Biology. -
Association between non-melanoma skin cancer and risk of fractures.
Mittal, V., Anderson, E. M., Kwon, G. P., Stefanick, M. L., Ransohoff, K. J., Hedlin, H. K., … Tang, J. Y. (2024). Association between non-melanoma skin cancer and risk of fractures. Skin Health and Disease, 4(1), e309. -
Incidence of Nonkeratinocyte Skin Cancer After Breast Cancer Radiation Therapy.
Rezaei, S. J., Eid, E., Tang, J. Y., Kurian, A. W., Kwong, B. Y., & Linos, E. (2024). Incidence of Nonkeratinocyte Skin Cancer After Breast Cancer Radiation Therapy. JAMA Network Open, 7(3), e241632. -
Functional Genotype-Phenotype Associations in Recessive Dystrophic Epidermolysis Bullosa.
So, J. Y., Nazaroff, J., Yenamandra, V. K., Gorell, E. S., Harris, N., Fulchand, S., … Tang, J. Y. (2024). Functional Genotype-Phenotype Associations in Recessive Dystrophic Epidermolysis Bullosa. Journal of the American Academy of Dermatology. -
Online, home-based dystrophic epidermolysis bullosa registry.
Mittal, V., Nazaroff, J., Eid, E., Li, S., Linos, E., Oro, A., & Tang, J. Y. (2024). Online, home-based dystrophic epidermolysis bullosa registry. Pediatric Dermatology. -
Evaluation of antipruritic effects of serlopitant, a neurokinin 1Ìýreceptor antagonist, in patients with epidermolysis bullosa: AÌýphase 2 randomized controlled trial.
Okata-Karigane, U., Pathmarajah, P., Gorell, E. S., Sum, K., Yekrang, K., Phung, M., … Chiou, A. S. (2024). Evaluation of antipruritic effects of serlopitant, a neurokinin 1Ìýreceptor antagonist, in patients with epidermolysis bullosa: AÌýphase 2 randomized controlled trial. Journal of the European Academy of Dermatology and Venereology : JEADV. -
A scalable and cGMP-compatible autologous organotypic cell therapy for Dystrophic Epidermolysis Bullosa.
Neumayer, G., Torkelson, J. L., Li, S., McCarthy, K., Zhen, H. H., Vangipuram, M., … Oro, A. E. (2024). A scalable and cGMP-compatible autologous organotypic cell therapy for Dystrophic Epidermolysis Bullosa. Nature Communications, 15(1), 5834. -
Phase 2 Trial of Topical Application of the Hedgehog Inhibitor Patidegib in Patients With Gorlin Syndrome.
Lear, J. T., Harwood, C. A., Hasan, Z., Kentley, J., Thomson, J., Khoo, A., … Tang, J. Y. (2024). Phase 2 Trial of Topical Application of the Hedgehog Inhibitor Patidegib in Patients With Gorlin Syndrome. The British Journal of Dermatology. -
Associations between dietary and supplemental vitamin A intake and melanoma and non-melanoma skin cancer.
Mittal, V., So, J. Y., Li, S., Swetter, S. M., Linos, E., Van Horn, L., … Tang, J. Y. (2024). Associations between dietary and supplemental vitamin A intake and melanoma and non-melanoma skin cancer. Skin Health and Disease, 4(6), e462. -
Functional genotype classification groups distinguish disease severity in recessive dystrophic epidermolysis bullosa.
Pathmarajah, P., Eid, E., Nazaroff, J., So, J., Mittal, V., Harris, N., … Tang, J. Y. (2025). Functional genotype classification groups distinguish disease severity in recessive dystrophic epidermolysis bullosa. The British Journal of Dermatology. -
Patient-Centered Research Through Artificial Intelligence to Identify Priorities in Cancer Care.
Kim, J., Chen, M. L., Rezaei, S. J., Ramirez-Posada, M., Caswell-Jin, J. L., Kurian, A. W., … Linos, E. (2025). Patient-Centered Research Through Artificial Intelligence to Identify Priorities in Cancer Care. JAMA Oncology.
-
Toxicity from radiation therapy associated with abnormal transcriptional responses to DNA damage
Clinical Trials
Clinical trials are ÌÇÐÄ´«Ã½ studies that evaluate a new medical approach, device, drug, or other treatment. As a ÌÇÐÄ´«Ã½ patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Practice Locations
Skin Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Skin Cancer Program in Palo Alto
900 Blake Wilbur Dr, 3rd Fl
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereGeneral Dermatology Clinic in Redwood City Redwood City, CA
Redwood City, CA
General Dermatology Clinic in Redwood City
450 Broadway, Pavilion B 4th Fl
Redwood City , CA 94063
Make An Appointment More Clinic Information Getting HereHigh-Risk Skin Cancer Clinic Redwood City, CA
Redwood City, CA
High-Risk Skin Cancer Clinic
450 Broadway, Pavilion B 4th Fl
Redwood City , CA 94063
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
ÌÇÐÄ´«Ã½, ÌÇÐÄ´«Ã½ Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by ÌÇÐÄ´«Ã½, ÌÇÐÄ´«Ã½ Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of ÌÇÐÄ´«Ã½, ÌÇÐÄ´«Ã½ Tri- Valley, or Stanford Medicine Partners. ÌÇÐÄ´«Ã½, ÌÇÐÄ´«Ã½ Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(58 reviews)
Dr. Tang and Dr. Voller provided excellent care.
Dr. Tang and her interns are the best...
Knowledgeable, kind, good patient care
Dr. Yang is professional and friendly.
Highest Rating!
Thank you for all the wonderful work
Excellent, concerned care
She ,a senior dermatology doctor, is absolutely full of experience and always replies my questions. She is excellent!
Dr. Tang is definitely one of the best doctors my husband and I have ever had. She has the unique ability to engage the patient in a partnership. She has such a respectful manner that we both feel comfortable with her. We both regard her highly.
Dr. Tang is wonderful; she is concerned, thorough, and very thoughtful.
Dr Tang was amazing! Friendly, caring, informative, thorough, upbeat
Professional and efficient.
she worked quickly but thoroughly to determine my issue
She’s very nice!
Care couldn't be better...Dt. Tang and her Interns are the best...
Dr. Tang is not just medically knowledgeable but she is also a caring doctor with broad medical expertise other than dermatology. She also knows her patient well enough to assure him/her any long term concern such as give me a thorough skin examination due to previous Mohs surgery
She is the Best
NOTHING BUT GOOD EXPERIENCES WITH DR. TANG
Dr. Tang is an excellent doctor. She's very empathetic and explained things well.
Dr. Tang is an excellent provider. She is caring and is sincere when discussing my needs and care regarding my condition.
Dr. Tang is well respected by her staff. I used to go to Valley Medical Center and they all (dermatologist) have worked with her. I will only go to Stanford Dermatology to see Dr. Tang.
Dr Tang is the absolute best. Worth waiting to see her. Thorough, caring and easy to understand.
Though not a tall glass, Dr. Tang is better than fresh-squeezed OJ.
DR. TANG IS VERY BUSY. WE'RE LUCKY TO HAVE HER
Dr. Tang is both professional and friendly and I trust her judgements and treatments. She is a perfect example of a good doctor in my estimation. The Dermatology Department has always been helpful, friendly, efficient and professional on my many visits.
I know the medication and went over some minute details with the doctor this time around. I explained that accutane the first time I had it cured chronic acne on my back which had reproduced and it's no cured. But, the dose requires some intricacy, and I used a true experience with a nice sun tan I had once and the tan cured temporarily my acne. But a sun burn did nothing to my acne and I just burned. So the even sun rays in correlation with accutane effects, I think that a lower dose would in fact key target all my acne and even the pores that are filled with puss. I had 100 mg which worked for one part of my body, which is my back. My face was treated with facials, using glycolic and tiny needles and lasers for my cysts and it worked. Hence my face needs accutane treatment. It should be simple, I estimated 70mg or so.
Dr. Tang is the BEST.
Very glad to be a Dr. Tang patient.
Dr. Tang is wonderful.
If I could've rated higher I would have. Dr. Tang & her interns are excellent care givers.
all went well and on time
The physician assistant was thorough but the dr. barely had any time for me.
Dr. Jean Tang is a very good doctor. I have itching for 18 years, went to so many dermatologists. She cured my itching.
Dr. Tang was fantastic. This was my 1st time seeing Dr. Jean Tang. Great doctor.
Very good team in this department!!!
I was lucky to see Dr. Tang. I had a 4-5 mos. wait to see Dr. Ko on a routine visit for a problem he missed several months earlier!!!
All went well
One word describes Dr. Tang: Terrific. She is amazing - Very knowledgeable, caring and all around wonderful doctor. Stanford is fortunate to have her. I feel blessed to have her as my doctor -
The resident (sorry; forgot her name) was very helpful by explaining every thing she did, and by answering all of my questions. OUTSTANDING bed side manner! I also appreciated Dr. Tang dropping in to say hello and asking if I had any questions.
Dr. Tang is amazing. She is the main reason I stay under the Stanford umbrella for health care (otherwise I would switch to be in the same system as my husband).
Excellent care & explaining.
A+ for Dr. Tang.
Dr. Tang is knowledgeable, thorough & I rec'd what I needed.
Dr. Tang is efficient, thorough and listens to my concerns.
Dr. Tang & her resident have excellent bedside manner.
Dr Tang is a good doctor.
Excellent doctor!!!
Excellent experience for first visit.
Dr. Tang is very good,
Only good experience plus confidence & trust in her medical knowledge.
Excellent.
Only negative is that Dr. Tang takes sabbaticals - so she isn't always available.
Dr. Tang is excellent in her knowledge regarding transplant patients.
Dr. Tang is excellent!
A+ - all super.
Very satisfied with provider.
She only works one day a week.
Dr. Tang is excellent in the field of post transplant patients care. She is the best.
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Phone:Ìý1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
ÌÇÐÄ´«Ã½ provides comprehensive services toÌýreferÌýandÌýtrack patients, as well as the latest information and news for physicians and office staff.ÌýFor help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
Ìý
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records